Latest news

• Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

  On the other hand, risdiplam has to be taken every day while Spinraza is dosed every four months after multiple injections in an initial loading period. ... Roche is also emphasising the safety of risdiplam, saying that “no treatment related safety

• Biogen’s R&D chief Ehlers heads for the exit

  s small-molecule drug risdiplam which is due to be filed before year end – the jury is out on future growth rates.

• Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

  Filings are also planned for anti-IL-6 antibody satralizumab for neuromyelitis optica and risdiplam, a small-molecule drug for spinal muscular atrophy (SMA) that would compete with Biogen’s Spinraza

• New products help lift Roche outlook despite biosimilar onslaught

  Severin Schwan. One of the firm's most promising late-stage pipeline projects is spinal muscular atrophy (SMA) project risdiplam, which is set to rival Biogen’s Spinraza.

• Biogen bounces back with Spinraza early treatment data

  Competition in SMA will further intensify with the anticipated future approval of Roche’s contender, risdiplam.